凝血问题:ATIII丰富的生物分子冠状病毒增强了PEG纳米颗粒的血液相容性
Vaidehi Londhe1, Manfred F Maitz1, Triantafyllos Chavakis2,3
1Leibniz-Institut für Polymerforschung Dresden e.V., Hohe Str. 6, 01069, Dresden, Germany.
Advanced healthcare materials
|June 30, 2025
概括
在纳米颗粒上利用生物分子冠状体与肝素-抗素III复合体可以减轻免疫反应并改善血红相容性. 这种方法对冠状体进行了工程设计,以提高纳米医学应用中的纳米粒子安全性.
科学领域:
- 生物材料科学 生物材料科学
- 纳米医学是一种纳米医学.
- 免疫学 免疫学 免疫学
背景情况:
- 纳米粒子在体内获得生物分子冠状,影响它们的生物身份和免疫相互作用.
- 低污染材料如聚乙烯甘醇 (PEG) 用于最大限度地减少蛋白质吸附并实现隐形性质,但很难完全预防冠状形成.
- 生物分子冠状体显著影响纳米粒子清除和免疫识别,对治疗应用提出了挑战.
研究的目的:
- 为了设计纳米颗粒的生物分子冠状,以克服免疫反应并改善血红相容性.
- 为了研究利用生物分子冠状的潜力,而不是防止其形成.
- 评估抗凝血剂氨酸-抗血III (HEP-ATIII) 复合体在减轻免疫和凝血反应中的作用.
主要方法:
- 使用的低污染的聚乙烯糖醇 (PEG) 纳米颗粒.
- 将纳米粒子生物分子冠状体与氨酸-抗氨酸III (HEP-ATIII) 复合体进行丰富.
- 进行免疫反应评估和蛋白质组分析.
- 评估了人类血液中的凝血反应.
主要成果:
- 单独使用PEG纳米颗粒就会诱导人体血液中的凝血反应.
- 用HEP-ATIII复合体预先丰富生物分子冠状体可以缓解这些凝固反应.
- 功能化纳米粒子保持了类似于裸体PEG纳米粒子的低污染和隐蔽特性.
- 研究结果表明,低污染和隐蔽性质并不能保证血红相容性.
结论:
- 生物分子冠状病毒工程提供了一种解决纳米医学挑战的策略,超越了简单预防蛋白质吸附的范围.
- 凝固是纳米医学材料设计的关键因素,必须与隐形性质一起考虑.
- 使用像HEP-ATIII这样的药物来功能化生物分子冠状体,可以导致更安全,更有效的治疗纳米材料.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
921
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
921
01:06Coagulation
384
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
384
02:45Blood Transfusion and Agglutination
11.3K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
11.3K
01:18Effects of EDTA on End-Point Detection Methods
353
Different methods, such as visual observance of metal-ion indicators, spectroscopic techniques, and potentiometric methods, can determine the endpoint of an EDTA titration.
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a...
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a...
353
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.3K